ROMIDEPSIN

Peak

romidepsin

NDAINTRAVENOUSSOLUTION
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT04747236Phase 2Recruiting

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Started Feb 2021
50 enrolled
PTCL
NCT04233697Phase 1Withdrawn

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Started Feb 2020
0
Lymphoma, T-Cell
NCT03547700Phase 1/2Active Not Recruiting

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Started Sep 2018
11 enrolled
Lymphoma, T-Cell, Peripheral
NCT02512497Phase 1Completed

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Started Dec 2017
23 enrolled
Cutaneous T-cell LymphomaT-Prolymphocytic LeukemiaT-Large Granulocytic Leukemia+2 more
NCT02616965Phase 1Completed

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Started Feb 2017
16 enrolled
Cutaneous T-cell Lymphoma (CTCL)